Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K8TO
|
|||
| Former ID |
DNCL002281
|
|||
| Drug Name |
AP1903
|
|||
| Synonyms |
Rimiducid; AP1903; 195514-63-7; UNII-H564L1W5J2; AP 1903; AP-1903; H564L1W5J2; Rimiducid [INN]; Rimiducid [USAN:INN]; CHEMBL269259; SCHEMBL10111062; DTXSID80173226; EX-A1711; AKOS030238859; CS-3162; KB-74710; HY-16046; Z-3163; 2-Piperidinecarboxylic acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) ester, (2S-(1(R*),2R*(S*(S*(1(R*),2R*)))))-
Click to Show/Hide
|
|||
| Indication | Transplant rejection [ICD-11: NE84; ICD-9: 279.5, 996] | Phase 1/2 | [1] | |
| Company |
Bellicum Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C78H98N4O20
|
|||
| Canonical SMILES |
CCC(C1=CC(=C(C(=C1)OC)OC)OC)C(=O)N2CCCCC2C(=O)OC(CCC3=CC(=C(C=C3)OC)OC)C4=CC(=CC=C4)OCC(=O)NCCNC(=O)COC5=CC=CC(=C5)C(CCC6=CC(=C(C=C6)OC)OC)OC(=O)C7CCCCN7C(=O)C(CC)C8=CC(=C(C(=C8)OC)OC)OC
|
|||
| InChI |
1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1
|
|||
| InChIKey |
GQLCLPLEEOUJQC-ZTQDTCGGSA-N
|
|||
| CAS Number |
CAS 195514-63-7
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | FK506-binding protein 1A (FKBP1A) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01744223) Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant. U.S. National Institutes of Health. | |||
| REF 2 | Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64. | |||
| REF 3 | Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10437-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.